key: cord-0957941-rwovxw7a authors: Villasis-Keever, Miguel A; López-Alarcón, Mardia G; Miranda-Novales, Guadalupe; Zurita-Cruz, Jessie N; Barrada-Vázquez, Aly S; González-Ibarra, Joaquín; Martínez-Reyes, Monserrat; Grajales-Muñiz, Concepción; Santacruz-Tinoco, Clara E; Martínez-Miguel, Bernardo; Maldonado-Hernández, Jorge; Cifuentes-González, Yazmín; Klünder-Klünder, Miguel; Garduño-Espinosa, Juan; López-Martínez, Briseida; Parra-Ortega, Israel title: Efficacy and Safety of Vitamin D Supplementation to Prevent COVID-19 in Frontline Healthcare Workers. A Randomized Clinical Trial date: 2022-04-18 journal: Arch Med Res DOI: 10.1016/j.arcmed.2022.04.003 sha: 7cef6fac39fdf5f879bfed26f44d27618bb6c06a doc_id: 957941 cord_uid: rwovxw7a BACKGROUND: . Associations between vitamin D (VD) deficiency and the risk of SARS-CoV-2 infection have been documented in cross-sectional population studies. Intervention studies in patients with moderate to severe COVID-19 have failed to consistently document a beneficial effect. OBJECTIVE: . To determine the efficacy and safety of VD-supplementation in the prevention of SARS-CoV-2 infection in highly exposed individuals. METHODS: . A double-blind, parallel, randomized trial was conducted. Frontline healthcare workers from four hospitals in Mexico City, who tested negative for SARS-CoV-2 infection, were enrolled between July 15 and December 30, 2020. Participants were randomly assigned to receive 4,000 IU VD (VDG) or placebo (PG) daily for 30 d. RT-PCR tests were taken at baseline and repeated if COVID-19 manifestations appeared during follow-up. Serum 25-hydroxyvitamin D3 and antibody tests were measured at baseline and at day 45. Per-protocol and intention-to-treat analysis were conducted. RESULTS: . Of 321 recruited subjects, 94 VDG and 98 PG completed follow-up. SARS-CoV-2 infection rate was lower in VDG than in PG (6.4 vs. 24.5%, p <0.001). The risk of acquiring SARS-CoV-2 infection was lower in the VDG than in the PG (RR: 0.23; 95% CI: 0.09–0.55) and was associated with an increment in serum levels of 25-hydroxyvitamin D3 (RR: 0.87; 95% CI: 0.82–0.93), independently of VD deficiency. No significant adverse events were identified. CONCLUSIONS: . Our results suggest that VD-supplementation in highly exposed individuals prevents SARS-CoV-2 infection without serious AEs and regardless of VD status. Introduction SARS-CoV-2, the cause of COVID-19, has led to more than 338 million cases and over 5.71 million deaths worldwide as for February 4, 2022 . Mexico is one of the most affected countries, with more than 5.03 million infections and more than 307,000 deaths (1) . COVID-19 pandemic coexists with vitamin D (VD) deficiency, which is also a major public health problem, both globally (2) (3) (4) and in Mexico (5) . This is relevant because of the well-known immunomodulatory role of VD as it attenuates Th1 cell and stimulates Th2 cell proliferation, favoring the synthesis and secretion of antiinflammatory cytokines, and limiting the production of pro-inflammatory mediators (6) . Therefore, it is expected that VD deficiency increases the susceptibility to bacterial and viral infections, including SARS-CoV-2. Very active research regarding VD and COVID-19 has been conducted in the last two years. Cross sectional, as well as large population-based studies have found an inverse correlation between serum 25-hydroxyvitamin D3 concentrations and SARS-Cov-2 positivity rate, severity, and mortality (7) (8) (9) (10) (11) (12) . Furthermore, meta-analyses of case-control and cohort studies conclude that individuals with lower 25-hydroxyvitamin D3 concentrations not only have an increased risk of SARS-CoV-2 positivity but are also more likely to require admission to intensive care units and to dye from the disease. However, most of these meta-analyses report a high degree of heterogeneity, and low precision or certainty of the analyzed studies (13) (14) (15) . The effect of VD supplementation to COVID-19 patients has been evaluated in intervention studies with inconsistent results probably due to differences in doses, duration of supplementation, evaluated outcomes, and sample size. For instance, Murai IH, et al. (16) failed to detect differences in hospital length-of-stay of patients with COVID-19 who received a high single VD dose compared to those who did not. In contrast, Quesada and his team reported that weekly high-dose calcifediol, a (17, 18) . Rastogi A, et al. found that patients with mild COVID-19 and VD deficiency, who received high oral doses of VD, tested negative for SARS-CoV-2 earlier than controls (19) . Thus, although it appears that VD supplementation of COVID-19 patients has a positive impact in disease outcomes, there is scarce information regarding the role of VD as a preventive measure to reduce the rate of SARS-Cov-2 infection in subjects with varying degrees of susceptibility. Therefore, we aimed to determine the efficacy and safety of VD supplementation to prevent SARS-CoV-2 infection in highly exposed individuals. Our primary outcomes were the rate of SARS-CoV-2 infection and the severity of the disease. Secondary endpoints included the reduction of VD deficiency prevalence and the frequency of treatment-associated adverse events (AEs). A multicenter, double-blind, parallel placebo-controlled, randomized clinical trial was conducted in Mexico City. Frontline healthcare workers from four tertiary-care hospitals converted to COVID-19 units were enrolled between July 15 and December 30, 2020, prior to vaccination. The protocol was approved by the institutional review boards of the Instituto Mexicano del Seguro Social (IMSS) system, which includes three hospitals (CNSI # R-2020-785-090) and the Hospital Infantil de México Federico Gómez (HIM 2020-045). All participants provided written informed consent. The study follows the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline. 6 We included SARS-Cov-2-free healthcare workers caring for hospitalized patients with COVID-19, who were not receiving supplementation with VD or other vitamins. Subjects with an immunocompromising condition, such as cancer or autoimmune disorders, were excluded. Subjects were randomly assigned to receive VD (VDG) or placebo (PG) in a 1:1 allocation fashion for 30 d. Randomization was conducted using a web software (Research Randomizer; https://www.randomizer.org/) by a senior researcher who had no contact with participants (MAVK). AEs were registered as per local regulatory requirements, including nausea, loss of appetite, vomiting, abdominal pain, diarrhea, headache, dizziness, drowsiness, constipation, muscle weakness, and rash. Information on whether the AEs were related to the study medication or resulting in medication discontinuation was also recorded. The presence of the virus was established in accordance with the Standardized Guidelines for Epidemiological Surveillance by a certified COVID-19 Laboratory (20) . SARS-CoV-2 was determined by RT-PCR. A result was considered positive if the sample showed amplification for any of the viral markers (Ct <37) and the RP control, and as negative a sample without amplification for viral markers, but with amplification for the RP control. Qualitative detection of IgG antibodies to SARS-CoV-2 in serum was determined with a chemiluminescent microparticle immunoassay (Alinity i and ARCHITECT i1000SR Abbott Systems, and LIAISON ® SARS-CoV-2 S1/S2 IgG, with LIAISON ® XL Analyzer of DiaSorin). A result was registered as positive if IgG antibodies to SARS-CoV-2 were higher than 5.0 AU/mL and S1/S2 IgG antibodies were higher than 15.0 AU/mL (21) . Nutrition, whose lab technicians are certified in such measurements. Concentration of 25hydroxyvitamin D3 was determined with the method described by Van Den Ouweland KM, et al. To test the hypotheses that VD supplementation can effectively to prevent SARS-CoV-2 infection and to improve VD status, relative risks (RR) and 95% CI were estimated. Two multivariate logistic regression models were used to identify explanatory variables. While in the first model the intervention (VD or placebo) was introduced as a covariate, in the second model we introduced the deltas of 25-hydroxyvitamin D3 concentration. Both models were adjusted by age, morbidity, and basal VD deficiency. Per protocol and intention-to-treat (ITT) analyses were conducted for primary and secondary outcomes; missing values of VD concentrations and AEs were assigned by multiple imputation. Of 407 screened healthcare workers, 321 met the inclusion criteria and were randomized (160 VDG, 161 PG). Ten VDG and 9 PG participants were excluded because of positive SARS-CoV-2 test; 56 VDG and 54 PG did not finish follow-up. The main reason for not completing the study was lack of time due to heavy workload. None of the participants decided to leave because of adverse events. Thus, 94 VDG and 98 PG were included in per protocol analysis, and 150 and 152 respectively for ITT analysis (Figure 1 ). Comparisons between dropouts and completers showed that VD deficiency was more frequent among dropouts (71 vs. 64% p = 0.008), but all the other studied variables were comparable. Most of the participants were physicians or nurses (55.4%), followed by laboratory technicians involved in blood handling of COVID-19 patients (23.7%); this distribution was comparable among the four studied hospitals and comparable between VDG and PG. PG subjects were older and exhibited a higher frequency of diabetes than VDG. The median 25-hydroxyvitamin D3 concentration ( (Figure 2A and 2B) . Accordingly, the risk of VD deficiency at the end of follow-up was lower in VDG than in PG ( Table 2 ). Six VDG and 24 PG tested positive for SARS-CoV-2 during follow-up (12 to RT-PCR and 18 to IgG antibody tests). The frequency of positive SARS-CoV-2 was 17.1% in VD deficient and 15.6% in non-deficient individuals ( 2 , p = 0.799). Nevertheless, the risk of acquiring SARS-CoV-2 infection was lower in VDG compared with PG in both, per-protocol, and ITT analyses ( Table 2) . While no subject in VDG required hospitalization or died, one PG participant was hospitalized with severe COVID-19 for 23 d and discharged home with mild respiratory symptoms. VDG than in the non-supplemented control group, independently of basal VD status (Table 3) . Another multivariate analysis revealed that increases of 25-hydroxyvitamin D3 predicted the risk of acquiring SARS-CoV-2 infection (Table 3 ). Both models were adjusted for age, comorbidities, vitamin D deficiency at baseline, as well as by site of study (hospital) and type of personnel. Thirty one percent of VDG and 32% of PG subjects reported at least one AE. The more frequently reported were headache, constipation, and diarrhea. While headache was more frequently reported in PG, constipation tended to be more common in VDG ( Table 4 ). The risk of presenting at least one AE was lower in VDG than in PG (Table 2 ), but in the ITT analysis that association was no longer significant. None of the AEs led to treatment discontinuation. Arch The results of our double-blind, placebo-controlled, prospective study demonstrate that VD supplementation is effective in preventing SARS-CoV-2 infection in high risk, frontline healthcare personnel. Furthermore, the protective effect of VD supplementation was independent of basal serum concentrations of 25-hydroxyvitamin D3. We have thus confirmed and extended the results of previous cross-sectional and intervention studies whereby vitamin sufficiency was found to be associated with better COVID-19 outcomes, including a lower requirement for intensive care unit admission and mortality rate (7, 17) . To our knowledge, this is the first controlled study evaluating the role of VD supplementation as a prophylactic measure to prevent SARS-Cov-2 infection and therefore has profound clinical and public health implications. VD is known to modulate the immune system (6, 24) . Both, the nuclear vitamin D receptor (VDR) and the vitamin D metabolizing enzymes are expressed in virtually all cells of the innate and The more frequently reported AEs were headache, intestinal transit alterations, nausea, abdominal pain, and fatigue, coinciding with VD-associated collateral effects. Nevertheless, the frequency and type of AEs were comparable between groups, which suggests that the perception of such symptoms may have been related to the acute stress derived from long working periods, or with the fear of acquiring COVID-19 as proposed by others (32) . The main strengths of our study are the randomized and experimental design, the inclusion of a highly exposed population, the use of a gold standard method to determine 25-hydroxyvitamin D3, Arch Med Res 22-00242 13 and the fact that it was conducted before vaccines against SARS-CoV-2 were available. Nevertheless, we recognize that the high proportion of participants who did not complete follow-up could lead to misinterpretation of the results by not identifying subjects with the disease among those who dropped the study. To deal with such situation, we performed an active surveillance on the hospitals' epidemiological records systems searching for dropouts among the confirmed SARS-CoV-2 positive, but none was identified. In addition, the association persisted in the ITT analysis, and confirmed after including confounders in the analysis. In conclusion, the findings of our study indicate that VD protects against SARS-CoV-2 infection in highly exposed individuals, regardless VD status and with relatively few side effects. Data described in the manuscript, code book, and analytic code will not be made available because it belongs to the Institutions where the study was conducted. The World Health Organization (WHO) Global prevalence and disease burden of vitamin D deficiency: a roadmap for action in low-and middle-income countries Vitamin D deficiency in Europe: pandemic? Vitamin D status in the United States Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales Regulation of immune function by vitamin D and its use in diseases of immunity SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels Role of vitamin D in preventing COVID-19 infection, progression and severity Severe vitamin D deficiency is not related to SARS-CoV-2 infection but may increase mortality risk in hospitalized adults: a retrospective case control study in an Arab Gulf country Vitamin D status of Arab Gulf residents screened for SARS-CoV-2 and its association with COVID-19 infection: a multi-centre case-control study Vitamin D and COVID-19 severity and related mortality: a prospective study in Italy Vitamin D Status and SARS-CoV-2 Infection and COVID-19 Clinical Outcomes Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and meta-analysis of 43 observational studies Low vitamin D status is associated with coronavirus disease 2019 outcomes: a systematic review and meta-analysis The role of vitamin D in the age of COVID-19: A systematic review and meta-analysis Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: A randomized clinical trial Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study Calcifediol treatment and COVID-19-related outcomes Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study) Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR SARS-CoV-2 IgG instructions for use. H14806R03. Available at Measurement of 25-OHvitamin D in human serum using liquid chromatography tandem-mass spectrometry with comparison to radioimmunoassay and automated immunoassay The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know Regulation of Immune Function by Vitamin D and Its Use in Diseases of Immunity A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19 Vitamin D supplementation as a rational pharmacological approach in the COVID-19 pandemic Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials Associations between predicted vitamin D status, vitamin D intake, and risk of SARS-CoV-2 infection and Coronavirus Disease 2019 severity Influence of 25-hydroxy-cholecalciferol levels on SARS-CoV-2 infection and COVID-19 severity: A systematic review and meta-analysis Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 supplementation on recovery of symptoms in patients with mild to moderate COVID-19: A randomized clinical trial Vitamin D supplementation and clinical outcomes in COVID-19: a systematic review and meta-analysis Frequency of acute stress disorder in health care workers of a tertiary level pediatric hospital during the National Safe Distance Strategy for COVID-19 prevention The study was supported with grants from the Instituto Mexicano del Seguro Social